Oculusgen (Ologen) Glaucoma MMC Control in Estonia
Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery
1 other identifier
interventional
20
1 country
1
Brief Summary
To compare the safety and effectiveness between ologen collagen matrix and mitomycin-C (MMC) in glaucoma surgery. The ologen collagen matrix implantation procedure is same as traditional trabeculectomy except implant the ologen collagen matrix on the top of sclera flap after one loose stich the sclera flap. The MMC application is as the standard.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Jul 2007
Typical duration for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2007
CompletedFirst Submitted
Initial submission to the registry
September 4, 2007
CompletedFirst Posted
Study publicly available on registry
September 5, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2011
CompletedJune 27, 2017
June 1, 2017
4.3 years
September 4, 2007
June 26, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
IOP <21mmHg without anti glaucoma medication
180 days
Secondary Outcomes (1)
IOP<21mmHg or IOP drops more than 30% with anti glaucoma medication
180-day
Study Arms (2)
Ologen in Trabeculectomy
EXPERIMENTALOlogen in Trabeculectomy
MMC in Trabeculectomy
ACTIVE COMPARATORMMC in Trabeculectomy
Interventions
Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
Eligibility Criteria
You may qualify if:
- Max anti glaucoma medication failed,
You may not qualify if:
- Age less than 18, woman in pregnant, hemodialysis patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tartu University Clinics
Tartu, Estonia
Related Publications (1)
Park J, Rittiphairoj T, Wang X, E JY, Bicket AK. Device-modified trabeculectomy for glaucoma. Cochrane Database Syst Rev. 2023 Mar 13;3(3):CD010472. doi: 10.1002/14651858.CD010472.pub3.
PMID: 36912740DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kuldar Kaljurand, MD
University of Tartu
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 4, 2007
First Posted
September 5, 2007
Study Start
July 1, 2007
Primary Completion
October 1, 2011
Study Completion
October 1, 2011
Last Updated
June 27, 2017
Record last verified: 2017-06